TGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasis

dc.contributor.authorStayrook, Keith R.
dc.contributor.authorMack, Justin K.
dc.contributor.authorCerabona, Donna
dc.contributor.authorEdwards, Daniel F.
dc.contributor.authorBui, Hai H.
dc.contributor.authorNiewolna, Maria
dc.contributor.authorFournier, Pierrick G.J.
dc.contributor.authorMohamma, Khalid S.
dc.contributor.authorWaning, David L.
dc.contributor.authorGuise, Theresa A.
dc.contributor.departmentDepartment of Pharmacology and Toxicology, IU School of Medicineen_US
dc.date.accessioned2017-07-11T17:54:35Z
dc.date.available2017-07-11T17:54:35Z
dc.date.issued2015-07-08
dc.description.abstractMechanistic understanding of the preferential homing of circulating tumor cells to bone and their perturbation on bone metabolism within the tumor-bone microenvironment remains poorly understood. Alteration in both transforming growth factor β (TGFβ) signaling and sphingolipid metabolism results in the promotion of tumor growth and metastasis. Previous studies using MDA-MB-231 human breast cancer-derived cell lines of variable metastatic potential were queried for changes in sphingolipid metabolism genes to explore correlations between TGFβ dependence and bone metastatic behavior. Of these genes, only sphingosine kinase-1 (SPHK1) was identified to be significantly increased following TGFβ treatment. Induction of SPHK1 expression correlated to the degree of metastatic capacity in these MDA-MB-231-derived cell lines. We demonstrate that TGFβ mediates the regulation of SPHK1 gene expression, protein kinase activity and is critical to MDA-MB-231 cell viability. Furthermore, a bioinformatic analysis of human breast cancer gene expression supports SPHK1 as a hallmark TGFβ target gene that also bears the genetic fingerprint of the basal-like/triple-negative breast cancer molecular subtype. These data suggest a potential new signaling axis between TGFβ/SphK1 that may have a role in the development, prognosis or the clinical phenotype associated with tumor-bone metastasis.en_US
dc.identifier.citationStayrook, K. R., Mack, J. K., Cerabona, D., Edwards, D. F., Bui, H. H., Niewolna, M., … Guise, T. A. (2015). TGFβ-Mediated Induction of SphK1 as a Potential Determinant in Human MDA-MB-231 Breast Cancer Cell Bone Metastasis. BoneKEy Reports, 4, 719. http://doi.org/10.1038/bonekey.2015.88en_US
dc.identifier.urihttps://hdl.handle.net/1805/13396
dc.language.isoen_USen_US
dc.publisherSpringerNatureen_US
dc.relation.isversionof10.1038/bonekey.2015.88en_US
dc.relation.journalBoneKEy Reportsen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectTumor cellsen_US
dc.subjectBone healthen_US
dc.subjectBone metabolismen_US
dc.subjectSphingolipid metabolismen_US
dc.subjectBone metastatisen_US
dc.subjectTumor-bone metastasis.en_US
dc.titleTGFβ-Mediated induction of SphK1 as a potential determinant in human MDA-MB-231 breast cancer cell bone metastasisen_US
dc.typeArticleen_US
ul.alternative.fulltexthttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495778/en_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
bonekey201588.pdf
Size:
2.82 MB
Format:
Adobe Portable Document Format
Description:
Original article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.88 KB
Format:
Item-specific license agreed upon to submission
Description: